# Hui Sheng Bio-pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hui-sheng-bio-pharmaceutical-co

- Industry: Biotechnology
- Headquarters: Meihekou, China
- Website: www.huishengpharm.com
- Total disclosed funding: $159M
- Latest round: Series A (Jan 4, 2023)
- Investors on record: 7

## About

Based in Jilin, China, and founded in 2019, Hui Sheng Bio-pharmaceutical Co,.Ltd. operates as a biopharmaceutical company specializing in the field of diabetes and complications treatment. As of 2022, it has more than 4,000 employees.

The company's product pipelines can be categorized into insulin and its analogues, GLP-1 analogues, biguanides, DPP-4 inhibitors, SGLT-2 inhibitors, glinides, and complications. It has more than 40 types of diabetes and complications product pipelines.

## Funding rounds

- Series A, Jan 4, 2023, $85M — Jilin Province Technology Investment, Jilin Equity Fund, Shanghai Angju Asset Management, Wuxi Shangxian Private Equity Fund Management
- Series A, Jun 1, 2022, $75M — Grand Flight Investment, China Life Capital, TONGHE DINGTAI INVESTMENT MANAGEMENT LIMITED

## Investors

- Grand Flight Investment (https://capitalatlas.ai/funds/grand-flight-investment) — Series A
- China Life Capital — Series A
- TONGHE DINGTAI INVESTMENT MANAGEMENT LIMITED — Series A
- Jilin Province Technology Investment (https://capitalatlas.ai/funds/jilin-province-technology-investment) — Series A
- Jilin Equity Fund (https://capitalatlas.ai/funds/jilin-equity-fund) — Series A
- Shanghai Angju Asset Management — Series A
- Wuxi Shangxian Private Equity Fund Management — Series A